Csongor György Lengyel, Baker Shalal Habeeb, Sara Cecilia Altuna, Dario Trapani, Shah Zeb Khan, Sadaqat Hussain
{"title":"The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience.","authors":"Csongor György Lengyel, Baker Shalal Habeeb, Sara Cecilia Altuna, Dario Trapani, Shah Zeb Khan, Sadaqat Hussain","doi":"10.1007/978-3-031-33602-7_14","DOIUrl":null,"url":null,"abstract":"<p><p>There is a growing global debate over barriers affecting the timely access to innovative anticancer therapies. Access to medicines is often traced back to the issue of costs: however, more commonly, the distance between valuable innovative treatments and the actual treatment of patients is far beyond the mere problem of financial barriers. A comprehensive approach to understand, assess to medicines should be pursued, to dissect the determinants and formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group \"ONCOLLEGE\".</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"188 ","pages":"353-368"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-031-33602-7_14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
There is a growing global debate over barriers affecting the timely access to innovative anticancer therapies. Access to medicines is often traced back to the issue of costs: however, more commonly, the distance between valuable innovative treatments and the actual treatment of patients is far beyond the mere problem of financial barriers. A comprehensive approach to understand, assess to medicines should be pursued, to dissect the determinants and formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group "ONCOLLEGE".
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
